- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
International Journal of Cell Biology
Volume 2011 (2011), Article ID 390238, 9 pages
Doxorubicin Induced Nephrotoxicity: Protective Effect of Nicotinamide
1Suleymaniye Woman Health Hospital, 34122 Istanbul, Turkey
2Department of Histology and Embryology, Cerrahpasa School of Medicine, Istanbul University, 34452 Istanbul, Turkey
3Department of Medical Biology, Cerrahpasa School of Medicine, Istanbul University, 34452 Istanbul, Turkey
4Department of Pharmacology, Meram School of Medicine, Selcuk University, 42080 Konya, Turkey
5Department of Histology and Embryology, Ege University School of Medicine, 35100 Izmir, Turkey
Received 31 January 2011; Revised 25 April 2011; Accepted 16 May 2011
Academic Editor: Richard Gomer
Copyright © 2011 Sule Ayla et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- P. K. Singal, C. M. R. Deally, and L. E. Weinberg, “Subcellular effects of adriamycin in the heart: a concise review,” Journal of Molecular and Cellular Cardiology, vol. 19, no. 8, pp. 817–828, 1987.
- E. Fadillioğlu, H. Erdoğan, S. Söğüt, and I. Kuku, “Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats,” Journal of Applied Toxicology, vol. 23, no. 1, pp. 71–74, 2003.
- A. Karaman, E. Fadillioglu, E. Turkmen, E. Tas, and Z. Yilmaz, “Protective effects of leflunomide against ischemia-reperfusion injury of the rat liver,” Pediatric Surgery International, vol. 22, no. 5, pp. 428–434, 2006.
- L. L. Liu, Q. X. Li, L. Xia, J. Li, and L. Shao, “Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats,” Toxicology, vol. 231, no. 1, pp. 81–90, 2007.
- F. H. Wapstra, H. Van Goor, P. E. De Jong, G. Navis, and D. De Zeeuw, “Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis,” Journal of Pharmacological and Toxicological Methods, vol. 41, no. 2-3, pp. 69–73, 1999.
- C. Nathan and Q. W. Xie, “Regulation of biosynthesis of nitric oxide,” Journal of Biological Chemistry, vol. 269, no. 19, pp. 13725–13728, 1994.
- R. Radi, J. S. Beckman, K. M. Bush, and B. A. Freeman, “Peroxynitrite oxidation of sulfhydryls: the cytotoxic potential of superoxide and nitric oxide,” Journal of Biological Chemistry, vol. 266, no. 7, pp. 4244–4250, 1991.
- J. C. Cendan, W. W. Souba, E. M. Copeland, and D. S. Lind, “Cytokines regulate endotoxin stimulation of endothelial cell arginine transport,” Surgery, vol. 117, no. 2, pp. 213–219, 1995.
- M. Fukuzawa, J. Satoh, G. Muto et al., “Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-α,” Immunology Letters, vol. 59, no. 1, pp. 7–11, 1997.
- L. Virág and C. Szabó, “The therapeutic potential of poly(ADP-ribose) polymerase inhibitors,” Pharmacological Reviews, vol. 54, no. 3, pp. 375–429, 2002.
- J. S. Ungerstedt, M. Blombäck, and T. Söderström, “Nicotinamide is a potent inhibitor of proinflammatory cytokines,” Clinical and Experimental Immunology, vol. 131, no. 1, pp. 48–52, 2003.
- S. Cuzzocrea, D. P. Riley, A. P. Caputi, and D. Salvemini, “Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury,” Pharmacological Reviews, vol. 53, no. 1, pp. 135–159, 2001.
- M. Yagmurca, H. Erdogan, M. Iraz, A. Songur, M. Ucar, and E. Fadillioglu, “Caffeic acid phenethyl ester as a protective agent against doxorubicin nephrotoxicity in rats,” Clinica Chimica Acta, vol. 348, no. 1-2, pp. 27–34, 2004.
- E. Beutler, “Active transport of glutathione disulfide from erythrocytes,” in Functions of Glutathione: Biochemical, Physiological, Toxicological, and Clinical Aspects, A. Lorsen, Ed., p. 65, Raven Press, 1988.
- H. W. Sharma and R. Narayanan, “The NF-κB transcription factor in oncogenesis,” Anticancer Research, vol. 16, no. 2, pp. 589–596, 1996.
- D. E. Paglia and W. N. Valentine, “Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase,” The Journal of Laboratory and Clinical Medicine, vol. 70, no. 1, pp. 158–169, 1967.
- R. L. Levine, D. Garland, C. N. Oliver et al., “Determination of carbonyl content in oxidatively modified proteins,” Methods in Enzymology, vol. 186, pp. 464–478, 1990.
- L. Raij, S. Azar, and W. Keane, “Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats,” Kidney International, vol. 26, no. 2, pp. 137–143, 1984.
- S. Hertzan-Levy, R. Fish, E. Skutelsky et al., “Glomerular basement membrane anionic sites in Adriamycin nephropathy: effect of saline loading and nitric oxide modulation,” Nephron, vol. 84, no. 4, pp. 354–361, 2000.
- Y. Wang, Y. P. Wang, Y. C. Tay, and D. C. H. Harris, “Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events,” Kidney International, vol. 58, no. 4, pp. 1797–1804, 2000.
- S. V. Shah, “Role of reactive oxygen metabolites in experimental glomerular disease,” Kidney International, vol. 35, no. 5, pp. 1093–1106, 1989.
- A. Deman, B. Ceyssens, M. Pauwels et al., “Altered antioxidant defence in a mouse adriamycin model of glomerulosclerosis,” Nephrology Dialysis Transplantation, vol. 16, no. 1, pp. 147–150, 2001.
- P. Deres, R. Halmosi, A. Toth et al., “Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound,” Journal of Cardiovascular Pharmacology, vol. 45, no. 1, pp. 36–43, 2005.
- T. M. Bray and C. G. Taylor, “Tissue glutathione, nutrition, and oxidative stress,” Canadian Journal of Physiology and Pharmacology, vol. 71, no. 9, pp. 746–751, 1993.
- P. Montilla, I. Túnez, M. C. Muñoz, A. López, and J. V. Soria, “Hyperlipidemic nephropathy induced by adriamycin: effect of melatonin administration,” Nephron, vol. 76, no. 3, pp. 345–350, 1997.
- L. F. Fajardo, J. R. Eltringham, J. R. Stewart, and M. R. Klauber, “Adriamycin nephrotoxicity,” Laboratory Investigation, vol. 43, no. 3, pp. 242–253, 1980.
- S. S. Sternberg, F. S. Philips, and A. P. Cronin, “Renal tumors and other lesions in rats following a single intravenous injection of daunomycin,” Cancer Research, vol. 32, no. 5, pp. 1029–1036, 1972.
- M. K. Irmak, E. Fadillioglu, S. Sogut et al., “Effects of caffeic acid phenethyl ester and alpha-tocopherol on reperfusion injury in rat brain,” Cell Biochemistry and Function, vol. 21, no. 3, pp. 283–289, 2003.
- M. M. Sayed-Aimed, “Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy,” Pharmacology and Toxicology, vol. 89, no. 3, pp. 140–144, 2001.
- P. Pacher, L. Liaudet, P. Bai et al., “Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction,” Circulation, vol. 107, no. 6, pp. 896–904, 2003.
- G. Tanrıverdi, The Analysis of the protective effects of nicotinamid's different doses on the liver damage induced carbon tetrachloride (CCl4) by light and electron microscopically, Research of dissertation, 2005.